HATC 是一种 HIF-1α AUTAC 降解剂,可将 HIF-1α 与 LC3 连接形成三元复合物,经自噬-溶酶体融合途径降解,从而在多种细胞类型中诱导剂量依赖性的 HIF-1α 降解,并可降低内脏脂肪堆积、肝脏脂质沉积、衰老细胞聚集和骨丢失,缓解年龄相关性椎间盘退变、肝功能异常、脊柱后凸及肺泡扩张,降低循环乳酸水平,改善体能,逆转年龄相关性粒细胞比例变化,延长中位寿命与最长寿命,降低转录组学年龄,且无明显的持续性毒性,可用于年龄相关性疾病的研究 (粉色:LC3 配体 (MS-P29952);蓝色:HIF-1α 配体 (MS-L37264);Linker:)。
HATC
产品编号: MS-W61661 分子式: C79H102ClN13O13 分子量: 1477.19
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

HATC 是一种 HIF-1α AUTAC 降解剂,可将 HIF-1α 与 LC3 连接形成三元复合物,经自噬-溶酶体融合途径降解,从而在多种细胞类型中诱导剂量依赖性的 HIF-1α 降解,并可降低内脏脂肪堆积、肝脏脂质沉积、衰老细胞聚集和骨丢失,缓解年龄相关性椎间盘退变、肝功能异常、脊柱后凸及肺泡扩张,降低循环乳酸水平,改善体能,逆转年龄相关性粒细胞比例变化,延长中位寿命与最长寿命,降低转录组学年龄,且无明显的持续性毒性,可用于年龄相关性疾病的研究 (粉色:LC3 配体 (MS-P29952);蓝色:HIF-1α 配体 (MS-L37264);Linker:)。

生物实验数据

生物活性 HATC is a HIF-1α AUTAC degrader that links HIF-1α to LC3 to form a ternary complex degraded via the autophagy-lysosome fusion pathway, thereby inducing dose-dependent HIF-1α degradation in multiple cell types, and it reduces visceral fat accumulation, hepatic lipid deposition, senescent cell accumulation, and bone loss; alleviates age-related intervertebral disc degeneration, hepatic dysfunction, kyphosis, and alveolar enlargement; lowers circulating lactate levels; improves physical performance; reverses age-related changes in granulocyte proportions; extends median and maximum lifespan; reduces transcriptomic age; and shows no obvious persistent toxicity, making it useful for research on age-related diseases (pink: LC3 ligand (MS-P29952); blue: HIF-1α ligand (MS-L37264); Linker:).
IC50 & Target

HIF-1α

 

体外研究
(In Vitro)

HATC (1-2 μM) 可在 5% 氧环境下强效诱导髓核 (NP) 细胞中 HIF-1α 的自噬降解,且浓度高达 2 μM 时无细胞毒性。
HATC 在缺氧条件下可诱导 293T 和 HeLa 细胞中 HIF-1α 的自噬降解。

体内研究
(In Vivo)

HATC (20 mg/kg;腹腔注射;每周 1 次) 可使老年 C57BL/6J 小鼠的中位寿命延长 14%,最长寿命延长 12.1%,同时在多项生理及病理衰老指标上改善健康寿命。
HATC (20 mg/kg;腹腔注射;每周 1 次) 可降低小鼠体内 HIF-1α 水平,缓解腰椎不稳诱导的椎间盘加速老化。

Animal Model: C57BL/6J mice (male and female, aged 20 months at treatment initiation)
Dosage: 20 mg/kg
Administration: i.p.; once weekly; until natural death
Result: Extended median lifespan by 14% and maximum lifespan by 12.1% compared to vehicle.
Mitigated age-associated weight gain and prevented rapid terminal weight loss, maintaining stable body weight until late life.
Reduced HIF-1α levels across multiple organs (lung, spleen, liver) compared to vehicle-treated aged mice.
Lowered predicted transcriptomic age in 24-month-old mice, with transcriptomic changes showing upregulation of pathways linked to improved organ function and metabolic health.
Reduced abdominal visceral fat accumulation and hepatic lipid deposition, prevented age-related increases in serum alanine aminotransferase and aspartate aminotransferase levels, and lowered circulating lactate levels to near young-mouse levels.
Improved multiple physical performance metrics (grip strength, maximal walking speed, bean balance time, hanging endurance, daily activity) to values approaching young mice.
Reduced age-related bone mass loss in female mice, improved spinal kyphosis index (lower spinal curvature), and attenuated age-dependent alveolar volume expansion in the lungs.
Reduced P16INK4a-positive senescent cells in organs, decreased inflammatory cell invasion in lung and liver, lowered circulating levels of SASP markers (IL-6, G-CSF), and reversed age-related increases in granulocyte proportion.
Reduced spontaneous tumor incidence by ~20% compared to vehicle-treated mice.
Animal Model: mice (aged 9 months at treatment initiation, LSI-induced aging model)
Dosage: 20 mg/kg
Administration: i.p.; once weekly; 3 months
Result: Significantly reduced HIF-1α levels in IVDs within 2 weeks of treatment initiation.
Alleviated age-related disc degeneration, as shown by improved histological scores on Safranin O/Fast Green staining, higher T2-weighted MRI signal intensity in IVDs, increased paw withdrawal threshold (reduced low back pain), and reduced P16INK4a-positive senescent cell accumulation in IVDs compared to vehicle-treated LSI mice.
Caused no overt toxicity or tissue damage in major organs (lung, spleen, liver) as assessed by H&E staining.

化学信息

分子量 1477.19
分子式 C79H102ClN13O13

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础